HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma
Kennedy S. Humphrey, Katherine J. Crawford, Bharani Muppavarapu, Melanie M. Mayberry, William Morris, Evan Torres, Mark D. Long, Jianxin Wang, Erik S. Knudsen, Agnieszka Katarzyna Witkiewicz, Ethan V. Abel
This paper identifies HNF1A as a BRD4 target and shows that BET-inhibitors' antitumor effects in PDAC depend on HNF1A ablation.
Communications Biology · Jul 30, 2026Peer-reviewedCancer Biology